BullFrog AI Partners with the Sage Group to Explore JV Opportunities to Advance its Oncology Assets
BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) announced a strategic partnership with the Sage Group to advance its Phase 2 ready oncology asset targeting glioblastoma, a deadly brain cancer, along with a preclinical prodrug asset. The partnership will leverage Sage Group's clinical and regulatory expertise to identify joint venture opportunities for global clinical development.
The glioblastoma treatment market is projected to exceed $10 billion by 2030, growing from $5.1 billion in 2020, highlighting significant market potential. BullFrog AI has exclusive licenses from Johns Hopkins University for innovative formulations of mebendazole, which have undergone clinical trials, aiming to provide new treatment options for patients.
- Strategic partnership with Sage Group to enhance oncology asset development.
- Access to clinical and regulatory expertise and capital resources.
- Significant market potential for glioblastoma treatment projected to surpass $10 billion by 2030.
- None.
BullFrog’s oncology assets have been acquired through exclusive licenses with Johns Hopkins University (JHU) and include a Phase 2 ready asset and a preclinical prodrug asset
GAITHERSBURG, Md., April 20, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG; BFRGW) ("BullFrog AI" or the "Company"), a digital technology company using machine learning to usher in a new era of precision medicine, today announced a strategic partnership with the Sage Group (www.sagehealthcare.com), a leader in the provision of strategic and transactional advice to healthcare and life science companies in the pharmaceutical, diagnostics, medical device, biotech, regenerative medicine, and cell and gene therapy fields.
The engagement will focus on seeking joint venture (JV) opportunities to further advance BullFrog AI’s Phase 2 ready asset targeting glioblastoma, an aggressive form of brain cancer, as well as the Company’s preclinical prodrug asset. The partnership will give BullFrog AI access to the Sage Group’s clinical and regulatory expertise, capital resources, and network of contacts, including innovators and large pharma.
"Glioblastoma is one of the deadliest forms of cancer, with a five-year survival rate of less than seven percent,” said BullFrog AI’s founder and CEO, Vin Singh. “With the Sage Group’s support, we look forward to identifying the right partner to help us advance clinical development of our oncology programs globally in an effort to bring a revolutionary new treatment option to glioblastoma patients.”
The market for glioblastoma treatment is expected to surpass
About BullFrog AI
BullFrog AI is a digital technology company using machine learning to usher in a new era of precision medicine. Through its collaborations with leading research institutions, including Johns Hopkins University, BullFrog AI is at the forefront of AI-driven drug development. Using its proprietary bfLEAP™ artificial intelligence platform, BullFrog AI aims to enable the successful development of pharmaceuticals and biologics by predicting which patients will respond to therapies in development. BullFrog AI is deploying bfLEAP™ for use at several critical stages of development with the intention of streamlining data analytics in therapeutics development, decreasing the overall development costs by decreasing failure rates for new therapeutics, and impacting the lives of countless patients that may seek to receive the therapies they need.
For more information visit BullFrogAI at
Website: www.bullfrogai.com
LinkedIn: https://www.linkedin.com/company/bullfrogai/
Safe Harbor Statement
This press release contains forward-looking statements. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.
Media Contacts:
BullFrog AI
Dave Gentry
RedChip Companies, Inc.
BFRG@redchip.com
800-733-2447
SOURCE: BullFrog AI Holdings, Inc.
FAQ
What is the focus of BullFrog AI's partnership with Sage Group?
What is the current market value for glioblastoma treatment?
What is the significance of BullFrog AI's assets developed with Johns Hopkins University?
What stage is BullFrog AI's oncology asset currently in?
